Spotlight on combination therapy development: strategic directions towards improving current I-O response rates

Dr Adil Daud is an expert in immunotherapy and has pioneered the development of novel immunotherapeutics and targeted therapies. His fellowship in medical oncology was at the Memorial Sloan Kettering Cancer Center and was a faculty member at the Moffitt Cancer Center in Tampa, Fl. He is currently Professor of Medicine and Dermatology at the University of California, San Francisco. He is the director of the Melanoma Program and melanoma clinical research at the Helen Diller Family Cancer Center at UCSF. He lead the development of IL-12 in melanoma and has developed novel technology to deliver it in vivo. He has played a major role in developing PD-1 antibodies in cancer therapy. Recently he has developed novel assays to determine immune responsiveness in vivo. These assays can determine the likelihood of response to immune therapy and provide novel insights into immune drug development. He has collaborated on numerous clinical and translational clinical trials that have yielded insights into the use of immunotherapy. A full list of publications is at https://profiles.ucsf.edu/adil.daud.

Please enter your email to access content Read now